It was suggested that somatic mutations in ASXL1, RUNX1 and SETBP1 as well as RAS pathway mutations had significant independent negative prognostic impact on CMML patients [21, 22]. This evidence concerns the gene ASXL1 and chronic myelomonocytic leukemia.